Rapid Response to the Combination of Lenvatinib and Pembrolizumab in Patients with Advanced Carcinomas (Lung Adenocarcinoma and Malignant Pleural Mesothelioma)

SIMPLE SUMMARY: Over the past decades, the multi-drug approach for treating various types of cancers was highly recommended. The aim of this study was to demonstrate the advantage of treating different carcinoma types with several combinations of immune checkpoint inhibitors (ICIs) and tyrosine kina...

Descripción completa

Detalles Bibliográficos
Autores principales: Shalata, Walid, Iraqi, Muhammed, Bhattacharya, Baisali, Fuchs, Vered, Roisman, Laila C., Cohen, Ahron Yehonatan, Massalha, Ismaell, Yakobson, Alexander, Prasad, Manu, Elkabets, Moshe, Porgador, Angel, Peled, Nir
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8307809/
https://www.ncbi.nlm.nih.gov/pubmed/34298855
http://dx.doi.org/10.3390/cancers13143630

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8307809/
https://www.ncbi.nlm.nih.gov/pubmed/34298855
http://dx.doi.org/10.3390/cancers13143630

Ejemplares similares